Joanna Wang, General Counsel, Insilico Medicine
Joanna Wang serves as the General Counsel and Board Secretary for Insilico Medicine, overseeing all legal matters worldwide, including financing, mergers and acquisitions, commercial transactions, intellectual property, corporate policies, and business strategies. Under her leadership, the legal team has facilitated the business development team in establishing various collaborations with global external clients, including pipeline drug development, drug discovery services and software solution services. This includes a drug R&D collaboration with Sanofi, potentially worth up to $1.2 billion targeting multiple objectives, and a drug licensing transaction for the ISM3091 project with the U.S.-listed company Exelixis, involving an upfront payment of $80 million. She and her team have also assisted the company in establishing headquarters in the U.S., subsidiaries in Canada and the UAE, and providing legal support for the daily operations of subsidiaries in seven jurisdictions. Additionally, they have robustly supported Insilico Medicine in conducting various clinical trial projects in the U.S., Australia, and other locations.
